KDR and colorectal carcinoma: Fruquintinib, a highly selective small molecule inhibitor of VEGFR-1, VEGFR-2 and VEGFR-3,is an orally available VEGFR inhibitor and widely used in the third-line treatment of metastatic colorectal cancer (CRC) (26).